Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.

You may also be interested in...

PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic

In this instance, FDA seems more interested than the sponsors in a potential market expansion.

PPI Efficacy Studies In Certain Infants May Be Needed, Cmte. Says

Proton pump inhibitor efficacy studies in certain infants under one year of age may be needed, members of FDA's Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee generally agreed at its June 11 meeting

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts